These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 17357336)

  • 1. Optimal maintenance therapy in patients with non-erosive reflux disease reporting mild reflux symptoms--a pilot study.
    Cibor D; Ciećko-Michalska I; Owczarek D; Szczepanek M
    Adv Med Sci; 2006; 51():336-9. PubMed ID: 17357336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg.
    Bigard MA; Genestin E
    Aliment Pharmacol Ther; 2005 Oct; 22(7):635-43. PubMed ID: 16181303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
    Baldi F; Morselli-Labate AM; Cappiello R; Ghersi S;
    Am J Gastroenterol; 2002 Jun; 97(6):1357-64. PubMed ID: 12094850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy of gastroesophageal reflux disease patients with omeprazole.
    Tepes B; Stabuc B; Kocijancic B; Ivanusa M
    Hepatogastroenterology; 2009; 56(89):67-74. PubMed ID: 19453031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux.
    Khoshoo V; Dhume P
    J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):352-4. PubMed ID: 18376260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy.
    Condra LJ; Morreale AP; Stolley SN; Marcus D
    Am J Manag Care; 1999 May; 5(5):631-8. PubMed ID: 10537869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
    Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease.
    Heyman MB; Zhang W; Huang B; Chiu YL; Amer F; Winter HS
    J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):35-40. PubMed ID: 17204950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease.
    Lee ES; Kim N; Lee SH; Park YS; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
    Aliment Pharmacol Ther; 2009 Jul; 30(2):154-64. PubMed ID: 19392871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?
    Boccia G; Manguso F; Miele E; Buonavolontà R; Staiano A
    Am J Gastroenterol; 2007 Jun; 102(6):1291-7. PubMed ID: 17319927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial.
    Konturek JW; Beneke M; Koppermann R; Petersen-Braun M; Weingärtner U
    Med Sci Monit; 2007 Jan; 13(1):CR44-9. PubMed ID: 17179910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study.
    Tsai HH; Chapman R; Shepherd A; McKeith D; Anderson M; Vearer D; Duggan S; Rosen JP;
    Aliment Pharmacol Ther; 2004 Sep; 20(6):657-65. PubMed ID: 15352914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term impact on quality of life in patients with gastroesophageal reflux disease after 52-week rabeprazole treatment].
    Yang XL; Liu XH; Ke MY; Song ZQ; Yuan YZ; Luo JY; Hou XH
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(34):2404-7. PubMed ID: 20137694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of preferences in patients with gastroesophageal reflux disease and dysphagia concerning treatment with lansoprazole orally disintegrating tablets].
    Blanco MA; Prieto M; Mearin F; Plazas MJ; Armengol S; Heras J; Mas M; Piqué JM;
    Gastroenterol Hepatol; 2009 Oct; 32(8):542-8. PubMed ID: 19595483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.
    Orenstein SR; Hassall E; Furmaga-Jablonska W; Atkinson S; Raanan M
    J Pediatr; 2009 Apr; 154(4):514-520.e4. PubMed ID: 19054529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies.
    Kushner PR; Snoddy AM; Gilderman L; Peura DA
    Postgrad Med; 2009 Jul; 121(4):67-75. PubMed ID: 19641272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.
    Miyamoto M; Haruma K; Kuwabara M; Nagano M; Okamoto T; Tanaka M
    J Gastroenterol Hepatol; 2007 May; 22(5):639-44. PubMed ID: 17444849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oesophageal acid exposure test in non-erosive gastroesophageal reflux disease and the diagnostic value of rabeprazole].
    Fan YH; Lü B; Zhan LX; Zhang L
    Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):475-7. PubMed ID: 17663823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-erosive and erosive gastroesophageal reflux diseases: No difference with regard to reflux pattern and motility abnormalities.
    Martínek J; Benes M; Hucl T; Drastich P; Stirand P; Spicák J
    Scand J Gastroenterol; 2008; 43(7):794-800. PubMed ID: 18584517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.